Tactile Systems Technology (NASDAQ:TCMD) Trading Down 9.6% - Time to Sell?
Tactile Systems Technology (NASDAQ:TCMD) saw its stock price decline by 9.6% on Thursday, with trading volume significantly below its daily average. Despite beating earnings estimates and analysts maintaining a "Moderate Buy" consensus with an average target of $37.40, a notable insider share sale occurred. The company, a medical device firm specializing in compression therapy systems, has a market capitalization of $674.44 million and is 83.43% institutionally owned.
Tactile Systems Technology (TCMD) Is Up 19.7% After Strong Q4, 2026 Outlook And LymphaTech Deal
Tactile Systems Technology (TCMD) reported strong Q4 2025 financial results with increased revenue and net income, alongside issuing optimistic 2026 revenue guidance of US$357 million to US$365 million. The company also announced the acquisition of LymphaTech, a digital lymphedema platform, integrating digital capabilities with its growth strategy. This news led to a significant 19.7% rise in TCMD's stock, though investors are cautioned about potential Medicare policy changes affecting future performance.
Tactile Systems Acquires LymphaTech To Expand Lymphedema Solutions Portfolio
Tactile Medical has acquired LymphaTech Inc. for $6.8 million, aiming to broaden its lymphedema solutions portfolio with digital and connected care technologies. LymphaTech specializes in a 3D full-body measurement and monitoring platform for lymphedema, offering precise measurements and tracking capabilities. This acquisition helps Tactile Medical move from being a product-based company to a comprehensive solutions leader for lymphatic dysfunction.
Tactile Systems Technology Shares Surge after Record-Breaking Q4 Earnings
Tactile Systems Technology (NASDAQ: TCMD) shares surged by over 18% following a record-breaking Q4 earnings report, surpassing revenue and EPS forecasts. The company achieved strong financial results with a 75% gross margin, $8.21M net income, and strategically acquired LymphaTech for $6.8M to enhance its digital health portfolio. This performance and strategic expansion have fueled investor confidence, indicating promising future growth and market prominence.
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
Tactile Medical has acquired LymphaTech Inc. for an upfront cash payment of $6.8 million, with additional payments contingent on future milestones. This acquisition aims to enhance Tactile Medical's lymphedema portfolio by integrating LymphaTech's 3D measurement and monitoring platform, which improves disease identification, accelerates therapy adoption, and supports next-generation lymphatic therapies. The integration is expected to strengthen Tactile Medical's market leadership and expand its research and development capabilities in treating lymphatic dysfunction.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q4 2025 Earnings Call Transcript
Tactile Medical reported strong Q4 and full-year 2025 financial results, with total revenue up 12% year-over-year to $329.5 million and adjusted EBITDA increasing 21% to $44.8 million. The company also announced the acquisition of LymphaTech, expanding its lymphedema solutions with digital 3D scanning technology. For 2026, Tactile Medical anticipates total revenue between $357 million and $365 million, representing 8% to 11% growth, while also addressing potential short-term impacts from new Medicare prior authorization requirements and continuing strategic investments in technology and sales force optimization.
Tactile Systems Technology Analysts Raise Their Forecasts After Better-Than-Expected Q4 Earnings
Tactile Systems Technology reported better-than-expected Q4 earnings and sales, surpassing analyst consensus. The company also provided a strong fiscal 2026 outlook and announced the acquisition of LymphaTech. Following these positive results, several analysts, including those from BTIG and Piper Sandler, raised their price targets for TCMD stock.
Tactile Systems Stock Smashes 52-Week High After Strong Quarter
Tactile Systems Technology (NASDAQ:TCMD) shares hit a 52-week high after reporting strong fourth-quarter earnings that surpassed analyst expectations and announcing the acquisition of LymphaTech. This strategic acquisition, aimed at enhancing lymphedema solutions, alongside robust financial performance and optimistic 2026 forecasts, has driven significant positive momentum for the stock. Analysts maintain a "Buy" rating with increased price targets, reflecting confidence in the company's growth trajectory and market position in the medical technology sector.
Tactile Systems Technology Inc (TCMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions Amid Regulatory Challenges
Tactile Systems Technology Inc (TCMD) reported a 12% increase in total revenue for 2025, reaching $329.5 million, with expanded gross margins and a 21% increase in adjusted EBITDA. The company also successfully repaid debt, repurchased stock, and acquired Lymphotec to enhance its lymphedema assessment capabilities. However, these positive developments are tempered by a new Medicare prior authorization requirement that may temporarily impact the lymphedema market and led to increased operating expenses.
Tactile Systems Technology Inc (TCMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions Amid Regulatory Challenges
Tactile Systems Technology Inc (TCMD) reported a 12% increase in revenue and 21% rise in adjusted EBITDA for 2025, driven by strategic investments and the acquisition of Lymphotec. The company successfully repaid debt and repurchased stock, ending the year with strong cash flow. Despite positive performance and strategic growth initiatives, the company anticipates a temporary slowdown in the lymphedema market due to new Medicare prior authorization requirements, which is reflected in their 2026 guidance.
Tactile Systems Technology Q4 Earnings Call Highlights
Tactile Systems Technology (NASDAQ: TCMD) reported strong double-digit revenue growth and improved profitability for Q4 and the full year 2025, driven by its lymphedema franchise and a significant increase in airway clearance revenue. The company also announced the acquisition of LymphaTech to enhance its integrated lymphedema solutions. Despite positive momentum, the 2026 outlook includes potential short-term disruption from a new Medicare prior authorization requirement for pneumatic compression devices, though management expects to mitigate the impact through prior investments and existing experience with similar authorization processes.
Tactile Systems Posts Strong Q4 Results and 2026 Outlook
Tactile Medical reported strong Q4 2025 results, with a 21% year-over-year revenue increase to $103.6 million and improved profitability. For the full year 2025, revenue grew 12% to $329.5 million, with net income reaching $19.1 million and adjusted EBITDA climbing to $44.8 million. The company strengthened its financial position, became debt-free, repurchased shares, and acquired LymphaTech, while also providing a positive 2026 outlook.
Tactile Systems Technology: Q4 Earnings Snapshot
Tactile Systems Technology Inc. (TCMD) reported strong fourth-quarter results, with earnings of $10.6 million and net income of 46 cents per share, surpassing Wall Street's expectations. The medical device company also exceeded revenue forecasts, posting $103.6 million for the quarter. For the full year, Tactile Systems Technology achieved a profit of $19.1 million on revenue of $329.5 million and projects future annual revenue between $357 million and $365 million.
Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio
Tactile Medical has acquired LymphaTech Inc. for $6.8 million upfront, plus potential future considerations. This acquisition expands Tactile Medical's lymphedema solutions portfolio by integrating LymphaTech's 3D measurement and monitoring platform, enhancing disease identification and treatment. The deal aims to strengthen Tactile Medical's market leadership and advance its research in lymphatic dysfunction.
Med-tech firm Tactile Medical wipes out $26.3M debt, lifts 2025 sales 12%
Tactile Medical reported strong Q4 and full-year 2025 financial results, with revenues increasing by 21% and 12% respectively. The company fully repaid its $26.3 million term loan and repurchased $26.5 million of stock, ending the year with $83.4 million in cash. Tactile Medical also provided optimistic 2026 guidance, projecting revenue growth of 8% to 11% and increased Adjusted EBITDA.
Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Tactile Systems Technology, Inc. announced strong financial results for Q4 and the full year 2025, with revenue growth of 21% and 12% respectively, driven by increases in both lymphedema and airway clearance product lines. The company also reported increased gross margin and Adjusted EBITDA for both periods, along with significant cash flow generation enabling debt repayment and share repurchases. For 2026, Tactile Medical projects continued revenue growth and a further increase in Adjusted EBITDA.
LSV Asset Management Grows Stock Holdings in Tactile Systems Technology, Inc. $TCMD
LSV Asset Management significantly increased its stake in Tactile Systems Technology ($TCMD) by 304.8% in Q3, acquiring 110,645 additional shares to own a total of 146,945 shares valued at approximately $2.03 million. The medical device company, specializing in lymphedema treatment systems, has received a "Moderate Buy" average analyst rating with an average target price of $28.75. Despite a recent insider sale, institutional investors now own 83.43% of the company's stock, which currently trades near $26.45 with a market capitalization of $590.89 million and a P/E ratio of 34.35.
Tactile Systems Technology (TCMD) Projected to Post Quarterly Earnings on Tuesday
Tactile Systems Technology (TCMD) is projected to release its Q4 2025 earnings before market open on Tuesday, February 17th, with analysts expecting $0.44 EPS. The company's stock currently trades at $27.30, with a market capitalization of approximately $610 million, and has seen recent insider selling by a VP. Institutional investors hold a significant portion of the stock, and analyst ratings are mixed, with a consensus of "Moderate Buy" and an average price target of $28.75.
(TCMD) Movement as an Input in Quant Signal Sets
This article analyzes Tactile Systems Technology Inc. (NASDAQ: TCMD) using AI models, highlighting a weak near and mid-term sentiment despite a positive long-term outlook. Key findings include an 84.4:1 risk-reward setup, targeting a 23.6% gain, and outlining three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis provides multi-timeframe signals, with strong long-term support and resistance levels.
Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
Tactile Medical announced it will release its financial results for the fourth quarter and fiscal year 2025 on February 17, 2026. The company will host a conference call and webcast on the same day to discuss these results. Interested parties can access the webcast or dial into the call to listen to the financial update.
Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
Tactile Medical announced it will release its fourth quarter and fiscal year 2025 financial results after the market closes on Tuesday, February 17, 2026. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss these results, with replay and archive options available. Tactile Medical specializes in at-home therapies for chronic conditions like lymphedema and lipedema.
Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
Tactile Medical (Nasdaq: TCMD) announced it will release its fourth quarter and fiscal year 2025 financial results after market close on February 17, 2026. The company will host a conference call and Q&A session at 5:00 p.m. ET on the same day for investors and analysts. Tactile Medical specializes in developing at-home therapies for chronic conditions such as lymphedema and chronic venous insufficiency.
Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026
Tactile Medical announced it will release its fourth quarter and fiscal year 2025 financial results after market close on Tuesday, February 17, 2026. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss these results. Details for participation and replay options have been provided for investors and interested parties.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Average Recommendation of "Moderate Buy" from Brokerages
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received an average recommendation of "Moderate Buy" from six brokerages, with an average twelve-month price target of $28.75. Recent analyst reports show varying ratings, including hold, buy, and strong buy, with some analysts setting price objectives as high as $35.00. Insider activity includes a VP selling shares, while institutional investors have adjusted their stakes in the company, which specializes in medical devices for lymphedema, reporting strong Q4 earnings and revenue of $85.76 million.
Tactile Systems Technology (TCMD) price target increased by 23.96% to 30.34
The article reports that the price target for Tactile Systems Technology (TCMD) has been increased by 23.96%, bringing it to $30.34. No further details are available as the provided content is minimal.
Tactile Systems Technology (TCMD) Price Target Increased by 23.96% to 30.34
The average one-year price target for Tactile Systems Technology (NasdaqGM:TCMD) has been increased by 23.96% to $30.34 per share, up from $24.48. This target represents a 1.32% increase from the last closing price. Institutional ownership shows a slight decrease in the number of funds, but an overall bullish outlook with a put/call ratio of 0.25.
TACTILE SYSTEMS TECHNOLOGY I (NASDAQ:TCMD) Shows Strong Growth and Technical Breakout Potential
Tactile Systems Technology Inc (NASDAQ:TCMD) exhibits strong growth potential, backed by solid financial health and a promising technical breakout pattern. The company shows consistent revenue and accelerating earnings growth, while its balance sheet is robust with no debt. Technically, TCMD is in a strong uptrend, outperforming peers, and appears poised for a further price move.
Tactile Systems Technology (NASDAQ:TCMD) Downgraded by Zacks Research to "Hold"
Zacks Research has downgraded Tactile Systems Technology (NASDAQ:TCMD) from a "strong-buy" to a "hold" rating, though the consensus analyst rating remains a "Moderate Buy" with an average target price of $28.75. The company recently beat quarterly earnings and revenue estimates, reporting $0.36 EPS against $0.16 expected, and $85.76M in revenue versus $79.31M expected. Insider selling activity was noted, with VP Kristie Burns selling over 5,000 shares, while institutional investors hold a significant portion of the stock.
Tactile Systems Technology (NASDAQ:TCMD) VP Sells $148,260.15 in Stock
Tactile Systems Technology (NASDAQ:TCMD) VP Kristie Burns sold 5,139 shares of company stock for $148,260.15 on January 2nd, reducing her stake by 6.63%. This transaction follows an earnings beat for the company, which reported EPS of $0.36 against an expected $0.16 and revenue of $85.76 million versus $79.31 million projected. Shares traded up 1.2% to $30.50, and institutional investors own 83.43% of the stock.
Tactile Systems Technology (NASDAQ:TCMD) shareholders are still up 114% over 3 years despite pulling back 7.6% in the past week
Tactile Systems Technology (NASDAQ:TCMD) has seen its share price increase by 114% over the past three years, demonstrating strong long-term growth despite a recent 7.6% dip. The company became profitable within this period, contributing to the significant share price appreciation. Additionally, the stock has gained 80% in the last quarter, indicating recent positive momentum.
Tactile Systems Technology (NASDAQ:TCMD) shareholders are still up 114% over 3 years despite pulling back 7.6% in the past week
Tactile Systems Technology's (NASDAQ:TCMD) share price has increased by 114% over the past three years, with an 80% rise in the last quarter despite a recent 7.6% weekly pullback. The company became profitable recently, contributing to the strong share price performance. Although recent returns are positive, the five-year trend shows an 8% annual loss, prompting caution.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Given Consensus Recommendation of "Moderate Buy" by Analysts
Tactile Systems Technology (NASDAQ:TCMD) has received a "Moderate Buy" consensus recommendation from analysts, with an average one-year price target of $21.67 and recent upgrades. Institutional ownership is notably high at 83.43%, with major increases from several investment firms. The company recently surpassed earnings and revenue estimates, trading around $27.40 with a market capitalization of approximately $612 million.
The Truth About Tactile Systems Tech (TCMD): Quiet Stock, Huge Upside – Or Total Trap?
Tactile Systems Tech (TCMD) is a medical technology company specializing in at-home devices for chronic swelling conditions. Despite not being a widely known stock, it is showing signs of recovery after a previous boom-and-bust cycle. The company's focus on "need-based" technology and recurring revenue from long-term patient relationships presents a potential upside for long-term investors willing to navigate its inherent risks and volatility.
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Tactile Systems Technology's shares have gained 28% in the last month, contributing to a 75% annual gain, despite its high P/E ratio of 36.4x compared to the market average. The company's strong earnings growth, which has outpaced most competitors and is projected to continue growing faster than the market, appears to justify this higher valuation. Investors seem confident in Tactile Systems Technology's future prospects, maintaining strong support for its share price.
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Tactile Systems Technology, Inc. has seen its shares jump 28% in the last month, bringing its annual gain to 75%. Despite having a P/E ratio of 36.4x, which is higher than nearly half the companies in the U.S., investors seem confident due to strong earnings growth and a forecast of 22% growth in the next year, outpacing the broader market's 16%. This suggests shareholders believe in the company's prosperous future and are therefore willing to accept a higher valuation.
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Tactile Systems Technology, Inc. (TCMD) shares have seen a significant 28% gain in the last month, contributing to an annual gain of 75%. The company's P/E ratio of 36.4x is considerably higher than the market average, driven by strong earnings growth of 20% in the last year and a projected 22% growth for the next year, outpacing the broader market's 16% forecast. This high P/E ratio suggests investors anticipate continued strong performance from Tactile Systems Technology.
Tactile Systems Technology (NASDAQ:TCMD) Hits New 52-Week High - Still a Buy?
Tactile Systems Technology (NASDAQ:TCMD) recently hit a new 52-week high of $28.18, trading significantly above its long-term technical trends. Despite a strong quarterly earnings beat and substantial institutional ownership, analyst ratings remain mixed, although some firms have upgraded the stock and raised price targets.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Given Average Rating of "Moderate Buy" by Brokerages
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received a consensus "Moderate Buy" rating from six brokerages, with an average 12-month price target of $21.67. The company recently exceeded EPS estimates and revenue expectations, and several firms have upgraded their ratings or increased price targets. TCMD shares are currently trading near their 52-week high, supported by significant institutional ownership.
Are Medical Stocks Lagging Tactile Systems Technology (TCMD) This Year?
Tactile Systems Technology (TCMD) is outperforming the Medical sector year-to-date, with a 51.4% return compared to the sector's 8.8%. The company holds a Zacks Rank #2 (Buy), and its full-year earnings estimates have seen a significant increase. Aveanna Healthcare (AVAH) is another Medical stock showing strong performance, up 102.9% this year.
Tactile Systems Technology (TCMD) is a Great Momentum Stock: Should You Buy?
Tactile Systems Technology (TCMD) has earned a Zacks Momentum Style Score of "A" and a Zacks Rank of #2 (Buy), indicating it is a strong momentum stock. The company's shares have significantly outperformed its industry and the S&P 500 over various timeframes, driven by strong short-term price activity and positive earnings estimate revisions. This makes TCMD a promising pick for momentum investors.
Tactile Systems Technology Repeat Insider Selling Not A Positive Indicator
Over the past year, several insiders at Tactile Systems Technology (NASDAQ:TCMD) have sold shares, which typically serves as a red flag for investors. Notably, the CEO sold US$96k worth of shares at a price below the current market value. While insiders still own a modest 2.1% of the company, the repeated selling activity, particularly when no insiders have purchased shares, suggests that shareholders should investigate further.
Tactile Systems Technology Repeat Insider Selling Not A Positive Indicator
Over the past year, several insiders at Tactile Systems Technology have sold shares, which could be a cause for concern for investors. The largest sale was by CEO Sheri Dodd, who sold shares below the current market price. While the total insider ownership remains significant at 2.1%, the consistent selling by multiple insiders suggests a need for shareholders to investigate further.
Zacks.com featured highlights include Tactile Systems, Canadian Natural Resources, Arlo and Celestica
This article highlights four "must-buy" efficient stocks identified by Zacks Equity Research: Tactile Systems Technology (TCMD), Canadian Natural Resources (CNQ), Arlo Technologies (ARLO), and Celestica (CLS). It explains common efficiency ratios like Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin that were used to select these companies. Each selected company is briefly described along with its average four-quarter earnings surprise.
Tactile Systems Technology (TCMD) Price Target Increased by 42.57% to 24.48
The average one-year price target for Tactile Systems Technology (NasdaqGM:TCMD) has increased by 42.57% to $24.48 per share, up from $17.17 on November 7, 2025. This average target, derived from multiple analyst estimates ranging from $16.16 to $33.60 per share, represents a 3.29% increase from the latest reported closing price of $23.70 per share. Fund sentiment indicates a bullish outlook with a put/call ratio of 0.73, despite a slight decrease in the number of institutional owners and total shares owned.
Tactile Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
Tactile Systems Technology, Inc. (Tactile Medical) will participate in the Piper Sandler 37th Annual Healthcare Conference. Management will hold a fireside chat on December 2nd at 8:00 a.m. Central Time, with a live audio webcast and archive available on their investor relations website. The company specializes in at-home therapies for chronic conditions such as lymphedema and chronic venous insufficiency.
Tactile Systems Technology (TCMD): Patent-Driven Innovation Poised to Unlock Lymphedema Market Share Gains
Tactile Systems Technology (TCMD) is positioned for significant growth in the lymphedema market due to its strategic buildup of a patent portfolio around pneumatic compression technologies. The company's recent Q3 2025 financial results exceeded expectations, driven by strong product adoption and an expansion of its Nimbl platform. This IP-driven leadership is expected to enable TCMD to outpace market growth, leading to substantial revenue increases and a re-rating of its valuation.
Tactile Systems Technology Reports Strong Q3 2025 Results
Tactile Systems Technology (TCMD) announced strong Q3 2025 financial results, with total revenue increasing by 17% to $85.8 million and net income rising to $8.2 million. The company reported improved gross margins, a significant increase in adjusted EBITDA, and a new $25 million share repurchase program. Tactile Medical also updated its 2025 financial outlook, projecting continued growth and financial flexibility after repaying a $24 million term loan.
Tactile Medical (Nasdaq: TCMD) authorizes $25M buyback, raises 2025 revenue outlook
Tactile Medical reported strong Q3 2025 results, with significant revenue growth and increased Adjusted EBITDA. The company also authorized a new $25 million share repurchase program, repaid its term loan, and raised its full-year 2025 revenue outlook. These actions reflect confidence in their strategic initiatives and market position.
Results: Tactile Systems Technology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Tactile Systems Technology, Inc. (NASDAQ:TCMD) exceeded its latest earnings expectations, reporting revenue of US$86m and statutory earnings per share (EPS) of US$0.36, significantly above estimates. Following these strong results, analysts have increased their forecasts for 2026, with an upgraded revenue projection of US$346.7m and EPS of US$0.92, alongside a 12% boost to their price target to US$18.83. This indicates a heightened optimism regarding the company's future performance, which is expected to grow in line with the broader medical equipment industry.
Tactile Systems Technology, Inc. to Release Third Quarter Fiscal Year 2025 Financial Results on November 3, 2025
Tactile Systems Technology, Inc. (Tactile Medical) will release its Q3 2025 financial results on November 3, 2025, after market close, followed by a conference call at 5:00 p.m. ET. The company, which provides at-home therapies for chronic conditions, will discuss its performance and engage with stakeholders. A replay of the call will be available for two weeks.
